EUVIMEDEUVIMED entdecken
Crossref

Reaching the target dose with one single 131 I‐mIBG administration in high‐risk neuroblastoma: The determinant impact of the primary tumour

Francesco Fiz iD, Alessio Cirone, Sergio Righi, Michela Massollo, Loredana Amoroso, Gianluca Bottoni, Massimo Conte, Monica Gambaro, Federico Massone, Stefano Orengo, Guido Semino Bruzzone, Stefania Sorrentino und 2 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Francesco Fiz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Neuroblastoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

131 I‐metaiodobenzylguanidine ( 131 I‐mIBG) effectiveness in children with metastasised neuroblastoma (NB) is linked to the effective dose absorbed by the target; a target of 4 Gy whole‐body dose threshold has been proposed. Achieving this dose often requires administering 131 I‐mIBG twice back‐to‐back, which may cause haematological toxicity. In this study, we tried identifying the factors predicting the achievement of 4 Gy whole‐body dose with a single radiopharmaceutical administration. Materials and methods : Children affected by metastatic NB and treated with a high 131 I‐mIBG activity (>450 MBq (megabecquerel)/kg) were evaluated retrospectively. Kinetics measurements were carried out at multiple time points to estimate the whole‐body dose, which was compared with clinical and activity‐related parameters.

Results

Seventeen children (12 females, median age 3 years, age range: 1.5–6.9 years) were included. Eleven of them still bore the primary tumour. The median whole‐body dose was 2.88 Gy (range: 1.63–4.22 Gy). Children with a ‘bulky’ primary (>30 mL) received a higher whole‐body dose than those with smaller or surgically removed primaries (3.42 ± 0.74 vs. 2.48 ± 0.65 Gy, respectively, p = .016). Conversely, the correlation between activity/kg and the whole‐body dose was moderate ( R : 0.42, p = .093). In the multivariate analysis, the volume of the primary tumour was the most relevant predictor of the whole‐body dose ( p = .002).

Conclusions

These data suggest that the presence of a bulky primary tumour can significantly prolong the 131 I‐mIBG biological half‐life, effectively increasing the absorbed whole‐body dose. This information could be used to model the administered activity, allowing to attain the target dose without needing a two‐step radiopharmaceutical administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsNeuroblastomaChildFemaleHumansInfantChild, PreschoolRadiometryRetrospective Studies3-IodobenzylguanidineIodine Radioisotopes

Stichwörter der Autor:innen

131I-mIBGadministration protocolneuroblastomapaediatricwhole-body dosimetry

Substanzen

Radiopharmaceuticals3-IodobenzylguanidineIodine Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy.
  • Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany.
  • Department of Medical Physics, Galliera Hospital, Genoa, Italy.
  • Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

ORCID-Profile: Francesco Fiz

Zitieren

APA

Fiz, F., Cirone, A., Righi, S., Massollo, M., Amoroso, L., Bottoni, G., Conte, M., Gambaro, M., Massone, F., Orengo, S., Bruzzone, G. S., Sorrentino, S., Garaventa, A., & Piccardo, A. (2024). Reaching the target dose with one single 131 I‐mIBG administration in high‐risk neuroblastoma: The determinant impact of the primary tumour. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30806

Vancouver

Fiz F, Cirone A, Righi S, Massollo M, Amoroso L, Bottoni G, et al. Reaching the target dose with one single 131 I‐mIBG administration in high‐risk neuroblastoma: The determinant impact of the primary tumour. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30806

BibTeX
@article{Fiz2024,
  author = {Fiz, Francesco and Cirone, Alessio and Righi, Sergio and Massollo, Michela and Amoroso, Loredana and Bottoni, Gianluca and Conte, Massimo and Gambaro, Monica and Massone, Federico and Orengo, Stefano and Bruzzone, Guido Semino and Sorrentino, Stefania and Garaventa, Alberto and Piccardo, Arnoldo},
  title = {Reaching the target dose with one single 131 I‐mIBG administration in high‐risk neuroblastoma: The determinant impact of the primary tumour},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30806}
}
Kostenlos starten →